On 26 November 2025, the European Commission withdrew the marketing authorisation for Integrilin (eptifibatide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, GlaxoSmithKline (Ireland) Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Integrilin was granted marketing authorisation in the EU on 1 July 1999 for prevention of early myocardial infarction. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2009. There are other generic medicinal products of eptifibatide authorised and marketed in the EU.
Therapeutic Indication
### Therapeutic indication Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).
Therapeutic Area (MeSH)
ATC Code
B01AC16
ATC Item
eptifibatide
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| eptifibatide | N/A | 依替巴肽 |
EMA Name
Integrilin
Medicine Name
Integrilin
Aliases
N/ANo risk management plan link.
